Rocky Ground For Monsanto?

The new spin-off must sell investors on ag biotech

Not long after taking over as chief executive officer of Monsanto Co. in 1995, Robert B. Shapiro instituted a program he called the two-in-the-box system. The idea was to pair up a technology or science expert with a business or marketing manager to share one job. Shapiro's hope was that the marriage of those managers in dozens of key positions would speed Monsanto's rollout of pharmaceutical or biotechnology products. It was the sort of bold management stroke that showed how, under Shapiro's leadership, Monsanto came to be run more like a high-tech startup than the agriculture and drug giant it was.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.